Skip to main content
We use cookies to improve our service and to tailor our content and advertising to you.
More info
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our
cookies policy
.
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Special Edition
Archive
Authors
About
Help
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Special Edition
Archive
Authors
About
Help
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are here
Home
Archive
Volume 12, Issue 4
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma
Email Alert
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Responses
Article
metrics
Alerts
PDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma
Statistics from Altmetric.com
Online download statistics by month:
Online download statistics by month: April 2019 to August 2019
Abstract
Full
Pdf
Apr 2019
1115
22
30
May 2019
1082
14
17
Jun 2019
578
2
1
Jul 2019
342
7
1
Aug 2019
67
3
2
Total
3184
48
51
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF